FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003522433> ?p ?o ?g. }

• W2003522433 endingPage "127" @default.
• W2003522433 startingPage "119" @default.
• W2003522433 abstract "Eribulin mesylate (Halaven®) is a novel inhibitor of microtubule dynamics that has demonstrated a survival benefit in patients with locally recurrent or metastatic breast cancer who previously received at least two chemotherapeutic regimens including an anthracycline and a taxane. Although trastuzumab is indicated for patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, a phase 1 study to evaluate tolerability/safety of eribulin mesylate with trastuzumab has not been conducted. Therefore, a study of eribulin mesylate in combination with trastuzumab was conducted to evaluate dose limiting toxicity (DLT), tolerability/safety, pharmacokinetics (PK), and efficacy and to estimate the recommended dose in Japanese patients with advanced or recurrent HER2+ breast cancer. Eribulin mesylate (1.4 mg/m(2)) was administered on days 1 and 8 of every 3 week cycle. Trastuzumab was administered with a 4 mg/kg loading dose followed by 2 mg/kg weekly doses or with an 8 mg/kg loading dose followed by 6 mg/kg tri-weekly doses. A total of 12 patients (six for each regimen) received eribulin mesylate and trastuzumab. No DLT was observed and the recommended dose of eribulin mesylate in combination with trastuzumab was estimated as 1.4 mg/m(2). Common adverse events were neutropenia, leukopenia, anaemia and alopecia. This combination therapy was well tolerated and the neutropenia observed was manageable. No PK drug-drug interaction between eribulin and trastuzumab was observed. Since a transient ejection fraction decreased was observed in two patients, cardiac function should be routinely assessed in patients receiving the combination therapy of eribulin mesylate with trastuzumab (ClinicalTrials.gov Identifier: NCT01432886)." @default.
• W2003522433 created "2016-06-24" @default.
• W2003522433 creator A5011974412 @default.
• W2003522433 creator A5014625956 @default.
• W2003522433 creator A5016141015 @default.
• W2003522433 creator A5034349158 @default.
• W2003522433 creator A5064272098 @default.
• W2003522433 creator A5076349434 @default.
• W2003522433 creator A5084325511 @default.
• W2003522433 creator A5084621690 @default.
• W2003522433 creator A5089829213 @default.
• W2003522433 date "2014-09-23" @default.
• W2003522433 modified "2023-09-27" @default.
• W2003522433 title "Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer" @default.
• W2003522433 cites W2004063005 @default.
• W2003522433 cites W2019607817 @default.
• W2003522433 cites W2048686497 @default.
• W2003522433 cites W2066693336 @default.
• W2003522433 cites W2074890479 @default.
• W2003522433 cites W2095156669 @default.
• W2003522433 cites W2095832858 @default.
• W2003522433 cites W2100014422 @default.
• W2003522433 cites W2100375606 @default.
• W2003522433 cites W2102838762 @default.
• W2003522433 cites W2106580933 @default.
• W2003522433 cites W2107960402 @default.
• W2003522433 cites W2115759102 @default.
• W2003522433 cites W2127152525 @default.
• W2003522433 cites W2132049943 @default.
• W2003522433 cites W2141393790 @default.
• W2003522433 cites W2159459001 @default.
• W2003522433 cites W2166242275 @default.
• W2003522433 cites W2318605753 @default.
• W2003522433 cites W4239462698 @default.
• W2003522433 doi "https://doi.org/10.1007/s10637-014-0161-y" @default.
• W2003522433 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4295025" @default.
• W2003522433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25242374" @default.
• W2003522433 hasPublicationYear "2014" @default.
• W2003522433 type Work @default.
• W2003522433 sameAs 2003522433 @default.
• W2003522433 citedByCount "13" @default.
• W2003522433 countsByYear W20035224332015 @default.
• W2003522433 countsByYear W20035224332016 @default.
• W2003522433 countsByYear W20035224332017 @default.
• W2003522433 countsByYear W20035224332018 @default.
• W2003522433 countsByYear W20035224332019 @default.
• W2003522433 crossrefType "journal-article" @default.
• W2003522433 hasAuthorship W2003522433A5011974412 @default.
• W2003522433 hasAuthorship W2003522433A5014625956 @default.
• W2003522433 hasAuthorship W2003522433A5016141015 @default.
• W2003522433 hasAuthorship W2003522433A5034349158 @default.
• W2003522433 hasAuthorship W2003522433A5064272098 @default.
• W2003522433 hasAuthorship W2003522433A5076349434 @default.
• W2003522433 hasAuthorship W2003522433A5084325511 @default.
• W2003522433 hasAuthorship W2003522433A5084621690 @default.
• W2003522433 hasAuthorship W2003522433A5089829213 @default.
• W2003522433 hasBestOaLocation W20035224331 @default.
• W2003522433 hasConcept C121608353 @default.
• W2003522433 hasConcept C126322002 @default.
• W2003522433 hasConcept C143998085 @default.
• W2003522433 hasConcept C197934379 @default.
• W2003522433 hasConcept C2775930923 @default.
• W2003522433 hasConcept C2776387010 @default.
• W2003522433 hasConcept C2776694085 @default.
• W2003522433 hasConcept C2777063308 @default.
• W2003522433 hasConcept C2778375690 @default.
• W2003522433 hasConcept C2779786085 @default.
• W2003522433 hasConcept C2781413609 @default.
• W2003522433 hasConcept C530470458 @default.
• W2003522433 hasConcept C71924100 @default.
• W2003522433 hasConcept C98274493 @default.
• W2003522433 hasConceptScore W2003522433C121608353 @default.
• W2003522433 hasConceptScore W2003522433C126322002 @default.
• W2003522433 hasConceptScore W2003522433C143998085 @default.
• W2003522433 hasConceptScore W2003522433C197934379 @default.
• W2003522433 hasConceptScore W2003522433C2775930923 @default.
• W2003522433 hasConceptScore W2003522433C2776387010 @default.
• W2003522433 hasConceptScore W2003522433C2776694085 @default.
• W2003522433 hasConceptScore W2003522433C2777063308 @default.
• W2003522433 hasConceptScore W2003522433C2778375690 @default.
• W2003522433 hasConceptScore W2003522433C2779786085 @default.
• W2003522433 hasConceptScore W2003522433C2781413609 @default.
• W2003522433 hasConceptScore W2003522433C530470458 @default.
• W2003522433 hasConceptScore W2003522433C71924100 @default.
• W2003522433 hasConceptScore W2003522433C98274493 @default.
• W2003522433 hasIssue "1" @default.
• W2003522433 hasLocation W20035224331 @default.
• W2003522433 hasLocation W20035224332 @default.
• W2003522433 hasLocation W20035224333 @default.
• W2003522433 hasLocation W20035224334 @default.
• W2003522433 hasOpenAccess W2003522433 @default.
• W2003522433 hasPrimaryLocation W20035224331 @default.
• W2003522433 hasRelatedWork W1937628254 @default.
• W2003522433 hasRelatedWork W2092771806 @default.
• W2003522433 hasRelatedWork W2102044848 @default.
• W2003522433 hasRelatedWork W2117882776 @default.
• W2003522433 hasRelatedWork W2560338447 @default.
• W2003522433 hasRelatedWork W2571164384 @default.

• next